Tluway Furahini, Makani Julie
Sickle Cell Programme, Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Br J Haematol. 2017 Jun;177(6):919-929. doi: 10.1111/bjh.14594. Epub 2017 Mar 14.
Sickle cell disease (SCD) is the single most important genetic cause of childhood mortality globally. Tanzania has one of the highest annual births of SCD individuals in the world, estimated to reach 11 000 births a year. Without intervention, 50-90% of children will die in childhood. However, cost-effective interventions have the potential to reduce childhood mortality by up to 70%. The effects of SCD are multi-dimensional, ranging from causing high morbidity and mortality, and reducing the quality of life, to imposing a high socio-economic burden on individuals, families and health systems. In the past 12 years, the SCD programme in Tanzania has developed, with local and global partnerships, a systematic framework for comprehensive research that is integrated into providing healthcare, training and advocacy in SCD. This report outlines the approach and achievements of collective initiatives for management and control of SCD in Tanzania.
镰状细胞病(SCD)是全球儿童死亡最重要的单一遗传原因。坦桑尼亚是世界上每年出生SCD患者数量最多的国家之一,估计每年有11000例出生。若不进行干预,50-90%的儿童将在童年期死亡。然而,具有成本效益的干预措施有可能将儿童死亡率降低多达70%。SCD的影响是多方面的,从导致高发病率和死亡率、降低生活质量,到给个人、家庭和卫生系统带来沉重的社会经济负担。在过去12年里,坦桑尼亚的SCD项目通过地方和全球伙伴关系,制定了一个全面研究的系统框架,该框架已融入SCD的医疗保健、培训和宣传工作中。本报告概述了坦桑尼亚在SCD管理和控制方面集体举措的方法和成就。